Barinthus Biotherapeutics (BRNS) Convertible Debt (2020)
Barinthus Biotherapeutics' (BRNS) quarterly Convertible Debt came in at $44.7 million in Q4 2020.
Barinthus Biotherapeutics (BRNS) Convertible Debt (2020) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 1 years of Convertible Debt data on file, last reported at $44.7 million in Q4 2020.
- Quarterly Convertible Debt changed N/A year-over-year to $44.7 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $44.7 million (changed N/A YoY) and the FY2020 annual result came in at $44.7 million, changed N/A from the prior year.
- Convertible Debt held at $44.7 million in Q4 2020.
- In the past five years, Convertible Debt ranged from a high of $44.7 million in Q4 2020 to a low of $44.7 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.01 Bn | 132.16 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn |
| 4 | Moderna | 60.18 Bn | 55.04 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.55 Bn | 28.24 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.19 Bn | 26.36 Bn | - |
| 10 | Barinthus Biotherapeutics | 25.29 Mn | 25.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 44.70 Mn |